Cases & Deals

  • Home
  • Practices
  • Baxter Ventures invests in True North Therapeutics

Share

Baxter Ventures invests in True North Therapeutics

June 2014

Client(s) Baxter International Inc.

Jones Day represented Baxter Ventures in connection with its purchase of Series A Preferred Stock in a private placement by True North Therapeutics, Inc., a biotechnology company that develops treatments for rare diseases. Co-investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, and Biogen Idec New Ventures.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.